Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA) - Hong Kong, China, 24 - 27 June 2002
(2002; 166 pages) View the PDF document
Table of Contents
View the documentAbbreviations and acronyms used in this report
Open this folder and view contentsOpening ceremony
Open this folder and view contentsHerbal medicines
Open this folder and view contentsKeynote address
Open this folder and view contentsSafety of blood-derived products
Open this folder and view contentsAntimicrobial resistance - new initiatives
Open this folder and view contentsHarmonization I
Open this folder and view contentsHarmonization II
Open this folder and view contentsProtection of trial subjects in clinical trials
Open this folder and view contentsRegulating biotechnology products
Open this folder and view contentsRegulatory challenges: health sector reform and drug regulatory capacity
Open this folder and view contentsAccess to drugs and vaccines I
Open this folder and view contentsAccess to drugs and vaccines II
Open this folder and view contentsCounterfeit pharmaceutical products
Close this folderHomoeopathy
View the documentRegistration criteria for homoeopathic medicinal products in the United Arab Emirates
View the documentThe regulatory framework for homoeopathic medicinal products in Germany and in the European Union
View the documentRegulation of homoeopathic products in the United Kingdom
View the documentRecommendations
Open this folder and view contentsSafety monitoring
Open this folder and view contentsE-Commerce
Open this folder and view contentsCurrent topics
Open this folder and view contentsRegulatory challenges of new technologies
View the documentList of participants
View the documentBack cover
 

Homoeopathy

Moderators: Dr Harald G. Schweim, Germany, and Ms

Yupin Lawanprasert, Thailand

Many drug regulatory authorities have little knowledge about homoeopathic principles, and are unsure how to evaluate the safety of these highly diluted products, how to carry out meaningful stability testing, or how to assess new homoeopathic products. Recent reports of adverse effects of homoeopathic treatment have raised concerns about how to ensure safety. The objectives of this session were to allow DRAs to exchange their knowledge and experience of regulation of homoeopathic medicines, discuss how to ensure quality control of the highly diluted products, and consider how to educate consumers in their proper use.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014